Loading...
•
Jun 30, 2023
Blueprint Medicines Q2 2023 Earnings Report
Blueprint Medicines delivered strong growth in AYVAKIT revenue and patients on therapy, achieved important regulatory and operational milestones, and nominated a selective and potent inhibitor of wild-type KIT.
Key Takeaways
Blueprint Medicines reported second quarter 2023 financial results, achieving $39.9 million in AYVAKIT/AYVAKYT net product revenues and $57.6 million in total revenues. The FDA approved AYVAKIT for adults with indolent systemic mastocytosis on May 22, 2023. The company also announced development candidate BLU-808 for treating mast cell disorders.
Achieved $39.9 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in Q2 2023.
Total revenues reached $57.6 million in Q2 2023.
AYVAKIT was approved by the FDA for treating adults with indolent systemic mastocytosis on May 22, 2023.
Announced development candidate BLU-808 for treating patients with mast cell disorders, including chronic urticaria.
Forward Guidance
Blueprint Medicines plans to achieve milestones by the end of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...